Merck's $10.8B Prometheus buyout can proceed after antitrust review

Nicole DeFeudis

Editor

The government’s waiting period for Merck’s $10.8 billion Prometheus Biosciences buyout expired on Monday, meaning the companies can proceed to close the deal, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's $10.8B Prometheus buyout can proceed after antitrust review

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Large vaccine makers stand by their investments despite US headwinds

Genentech vet launches ADC startup with $20M

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Merck's $10.8B Prometheus buyout can proceed after antitrust review